About Akero Therapeutics
Akero Therapeutics is a company based in San Francisco (United States) founded in 2017 was acquired by Novo Nordisk in October 2025. Akero Therapeutics has raised $135 million across 4 funding rounds from investors including Pfizer, Novo Nordisk and Janus Henderson Investors. The company has 63 employees as of December 31, 2024. Akero Therapeutics offers products and services including Efruxifermin (EFX). Akero Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
- Headquarter San Francisco, United States
- Employees 63 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Akero Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$252.06 M (USD)-66.09as on Dec 31, 2024
-
EBITDA
-$285.4 M (USD)-65.13as on Dec 31, 2024
-
Total Equity Funding
$135 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jun 16, 2022
-
Investors
Pfizer
& 11 more
-
Employee Count
63
as on Dec 31, 2024
-
Acquired by
Novo Nordisk
(Oct 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Akero Therapeutics
Akero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AKRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Akero Therapeutics
Akero Therapeutics offers a comprehensive portfolio of products and services, including Efruxifermin (EFX).
Investigational treatment for metabolic dysfunction-associated steatohepatitis.
People of Akero Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Akero Therapeutics
Akero Therapeutics has successfully raised a total of $135M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Akero Therapeutics
Akero Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novo Nordisk and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare startups are funded by this corporate-backed venture capital entity.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Locked | Locked | Locked |
Investor details for Akero Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Akero Therapeutics
Investment portfolio details for Akero Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Akero Therapeutics
Detailed financials for Akero Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Akero Therapeutics Comparisons
Peer comparison for Akero Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Akero Therapeutics
Akero Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
Detailed competitors of Akero Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Akero Therapeutics
Complete news archive for Akero Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akero Therapeutics
Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Akero Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Akero Therapeutics is 63.
Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.
Akero Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Akero Therapeutics offers Efruxifermin (EFX).
Yes, Akero Therapeutics is publicly traded on NASDAQ under the ticker symbol AKRO.
Akero Therapeutics has 12 investors. Key investors include Pfizer, Novo Nordisk, Janus Henderson Investors, Atlas Venture, and LifeSci Venture Partners.
The ticker symbol of Akero Therapeutics is AKRO on NASDAQ.